Assembly BiosciencesASMB
About: Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Employees: 73
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
222% more capital invested
Capital invested by funds: $15.6M [Q3] → $50.3M (+$34.7M) [Q4]
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
33.86% more ownership
Funds ownership: 16.23% [Q3] → 50.09% (+33.86%) [Q4]
17% more funds holding
Funds holding: 30 [Q3] → 35 (+5) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Guggenheim Vamil Divan 35% 1-year accuracy 9 / 26 met price target | 230%upside $31 | Buy Initiated | 25 Mar 2025 |
Financial journalist opinion
